Results 151 to 160 of about 27,793 (201)

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +1 more source

Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. [PDF]

Antimicrob Agents Chemother
van Dyk J, Waitt C, Mugerwa H, Wiesner L, Orrell C, Bamford A, Gibb DM, McIlleron HM, Colbers A, Burger DM, Denti P, Wasmann RE.   +11 more
europepmc   +1 more source

Incidence and correlates of chronic anemia in people living with HIV Initiating ART: An exploratory five-year retrospective cohort of patients retained in care. [PDF]

PLOS Glob Public Health
Kamvuma K, Hamooya BM, Mulemena JA, Masenga SK, Kirabo A, Munsaka SM.   +5 more
europepmc   +1 more source

Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue. [PDF]

Einstein (Sao Paulo)
Zanardo LW, Izabel LDS, Hamada LM, Carvalho MB, Silva PAGOE, Joaquim HDG, Santoro S, Festuccia WT, Magdalon J.   +8 more
europepmc   +1 more source

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. [PDF]

Clin Infect Dis
Obeng BM, Hutchinson J, Shaik A, Chetchotisakd P, Azwa I, Wulan WN, Kumarasamy N, Wolff M, Bruguera J, Losso M, Kaplan R, Diallo MS, Eriobu N, Musoro G, Kumalawati J, Badamasi A, Fitriah M, Mulya DP, Law M, Matthews G, Di Giallonardo F, Kelleher AD, Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group.   +22 more
europepmc   +1 more source

Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK–MDR1, and Caco-2 cell monolayers

Journal of Pharmaceutical Sciences, 2009
Bidirectional transport studies were conducted using Caco-2, MDCK, and MDCK-MDR1 to determine P-gp influences in lamivudine and zidovudine permeability and evaluate if zidovudine permeability changes with the increase of zidovudine concentration and/or ...
Sílvia Storpirtis, Leslie Z. Benet, Jacqueline De Souza   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Metabolism of zidovudine

General Pharmacology: The Vascular System, 1995
1. The anti-HIV drug zidovudine (3'-azido-2',3'-dideoxythymidine; ZDV) has three important pathways of metabolism. ZDV is a prodrug and must be phosphorylated in lymphocytes in order to exert its antiviral action. However, in quantitative terms this is a minor pathway probably accounting for less than 1% of the overall metabolic profile.
G J, Veal, D J, Back
openaire   +2 more sources

The Use of Zidovudine

International Journal of Dermatology, 1989
La zidovudine est actuellement le seul medicament disponible pour le traitement des infections par HIV et ses indications sont encore mal connues. Etant donne la toxicite de la zidovudine constatee lors de differentes etudes, notamment la toxicite medullaire et hematologique et le cout eleve du traitement, il n'y a aucune indication a utiliser cette ...
openaire   +2 more sources

Zidovudine and dementia

Nursing Standard, 1989
AIDS dementia complex may be prevented by treatment with antiviral agents.
openaire   +2 more sources

Zidovudine Intolerance

Clinical Infectious Diseases, 1990
Patients may be intolerant of zidovudine for several reasons, the most prominent being hematologic toxicity. In vitro studies demonstrate that zidovudine is toxic to the myeloid and erythroid precursors in the bone marrow; at concentrations of zidovudine near those associated with the optimal antiviral effect in vitro, the proliferative capability of ...
openaire   +2 more sources